Jump to main content
Jump to site search

Issue 35, 2017
Previous Article Next Article

Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis

Author affiliations

Abstract

Nuclear Magnetic Resonance Imaging (MRI) of amyloid plaques is a powerful non-invasive approach for the early and accurate diagnosis of Alzheimer's disease (AD) along with clinical observations of behavioral changes and cognitive impairment. The present article aims at giving a critical and comprehensive review of recent advances in the development of nanoparticle-based contrast agents for brain MRI. Nanoparticles considered for the MRI of AD must comply with a highly stringent set of requirements including low toxicity and the ability to cross the blood–brain-barrier. In addition, to reach an optimal signal-to-noise ratio, they must exhibit a specific ability to target amyloid plaques, which can be achieved by grafting antibodies, peptides or small molecules. Finally, we propose to consider new directions for the future of MRI in the context of Alzheimer's disease, in particular by enhancing the performances of contrast agents and by including therapeutic functionalities following a theranostic strategy.

Graphical abstract: Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis

Back to tab navigation

Publication details

The article was received on 12 Jun 2017, accepted on 28 Jul 2017 and first published on 28 Jul 2017


Article type: Review Article
DOI: 10.1039/C7TB01599B
Citation: J. Mater. Chem. B, 2017,5, 7216-7237
  •   Request permissions

    Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis

    D. Azria, S. Blanquer, J. Verdier and E. Belamie, J. Mater. Chem. B, 2017, 5, 7216
    DOI: 10.1039/C7TB01599B

Search articles by author

Spotlight

Advertisements